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Introduction: This retrospective cohort study was designed to 
analyze factors associated with administration of chemotherapy 
and to examine the impact of chemotherapy on survival among 
elderly patients with small-cell lung cancer (SCLC) in the 
community.
Methods: Elderly patients aged 65 years and older with SCLC diag-
nosed between 1992 and 2001 were selected from the Surveillance, 
Epidemiology, and End Results–Medicare database. Logistic regres-
sion was used to evaluate which covariates influenced receipt of che-
motherapy. Cox proportional hazards regression was used to examine 
the influence of clinical and demographic variables on survival. The 
independent effect of chemotherapy on survival was determined 
using propensity scores and quantile regression.
Results: In the final cohort of 10,428 patients, 67.1% received chemo-
therapy, 39.1% received radiation, 3.4% received surgery, and 21.8% 
received no treatment. The most common chemotherapy regimens 
included etoposide combined with either cisplatin or carboplatin. 
Patients aged 85 years and older were significantly less likely to receive 
chemotherapy compared with patients aged 65 to 69 years (odds ratio 
0.17; 95% confidence interval 0.14–0.21). Median survival for all 
patients was 7 months. Factors associated with improved survival were 
being female, black race, having limited-stage disease, receiving any 
treatment, and having a lower comorbidity score. Quantile regression 
demonstrated that chemotherapy provided a 6.5-month improvement 
in median survival (95% confidence interval 6.3–6.6; p<0.001).
Conclusions: Statistically significant differences in the receipt of che-
motherapy exist among elderly patients with SCLC. Chemotherapy 
is associated with a greater than 6-month improvement in median 
survival among elderly patients with SCLC, even in patients over the 
age of 80 years.
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The American Cancer Society estimates that there will be 228,190 new cases of lung cancer diagnosed in the United 
States in 2013.1 Lung cancer is associated with the highest 
mortality rate of any cancer in the United States, with 159,480 
deaths predicted in 2013. Lung cancer will be responsible 
for 27.5% of all cancer deaths in the United States this year. 
Indeed, it kills more people than colorectal cancer, breast 
cancer, pancreatic cancer, and prostate cancer combined, the 
second through fifth leading causes of cancer mortality in 
the United States, respectively.1 Approximately 14% of lung 
cancer cases have small-cell histology, which corresponds 
to more than 30,000 cases of small-cell lung cancer (SCLC) 
annually.2,3
Five-year survival for lung cancer is 16.9%.4 Overall 
5-year survival for SCLC is only 6.6%.5 For limited-stage 
SCLC, 5-year survival is 12.1%; for extensive-stage disease, 
5-year survival is only 1.6%.5–7
The National Comprehensive Cancer Network recom-
mends concurrent chemoradiation as the standard treatment 
for limited-stage SCLC.8 For extensive-stage disease, the rec-
ommended treatment is chemotherapy alone; radiation can 
be administered for symptomatic relief of metastatic sites. 
Surgery is less commonly used in the treatment of SCLC 
and is usually considered only for treatment of patients with 
T1N0 or T2N0 disease, followed by chemotherapy with or 
without radiation. Cisplatin and etoposide or carboplatin and 
etoposide are the two most commonly used regimens in the 
treatment of SCLC.6,7 Another treatment option is cyclophos-
phamide, doxorubicin, and vincristine (the CAV regimen). For 
relapsed disease, a number of chemotherapeutic options are 
available, including topotecan. Patients who have a complete 
response to chemotherapy should undergo prophylactic cra-
nial irradiation.9,10
Although numerous randomized clinical trials (RCTs) 
have demonstrated a benefit of chemotherapy for patients with 
SCLC, these trials have predominantly compared different 
chemotherapy regimens rather than comparing chemother-
apy to best supportive care (BSC).6,7 Some of them included 
chest radiation or prophylactic cranial irradiation. Moreover, 
many RCTs excluded elderly patients or those with signifi-
cant medical comorbidities.11 In a study by Ramsey et al.,12 
non–small-cell lung cancer (NSCLC) patients who received 
chemotherapy lived 2 to 4 months longer than those who 
did not. The purpose of this retrospective cohort study is to 
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present factors associated with the receipt of chemotherapy 
and to quantify the benefit of chemotherapy on survival of 
elderly patients with SCLC in the community. This is the first 
large-scale analysis of chemotherapy use among patients with 
SCLC in the community setting.
MATERIALS AND METHODS
Data Sources
The National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) database contains 
information on nearly 5,000,000 cases of cancer diagnosed 
between 1973 and 2005 in the United States. The catchment 
area includes 26.2% of the U.S. population and includes 18 
geographical areas. Although the database contains demo-
graphic information, primary site, histology, date of diag-
nosis, stage, treatment with surgery and radiation given in 
the first course of treatment, vital status, date and cause of 
death, and survival in months, it does not contain informa-
tion about chemotherapy, smoking, comorbidities, or perfor-
mance status.
To obtain chemotherapy and comorbidity information 
for these patients, the SEER-Medicare database was used. 
The Centers for Medicare and Medicaid Services Medicare 
database includes 97% of Americans aged 65 years and 
older. The SEER database has been linked to the Medicare 
database using a unique registration number for each patient. 
The merged SEER-Medicare database contains 94% of can-
cer patients aged 65 years and older in the SEER database.13 
Information about chemotherapy, comorbidities, and census 
data is included in the SEER-Medicare database. The SEER-
Medicare database contains information on 312,886 cases 
of lung cancer diagnosed between 1973 and 2002. We used 
the inpatient records, outpatient records, and physician bill-
ing claims. Follow-up data were available until December 
of 2004.
Patient Selection Criteria
Cases of SCLC were identified using the International 
Classification of Diseases for Oncology, third edition (ICD-
O-3) codes 8041 to 8045. Of 312,886 cases of lung cancer, 
43,013 were SCLC (13.7%). Patients who were diagnosed 
with SCLC between January of 1992 and December of 2001 
were selected from the SEER-Medicare database (25,551 
cases). Those younger than 65 years (3351 cases, 13.1%) 
or who had more than one primary were excluded. Patients 
enrolled in a health maintenance organization (HMO) were 
excluded because chemotherapy information for them was 
not complete. Likewise, patients were required to have both 
Medicare parts A and B to have complete information about 
chemotherapy and comorbidities. Usage of these exclusion 
criteria ensured that all the patients in this study had the same 
insurance. Patients diagnosed by autopsy or death certifi-
cate could not be analyzed for survival and, therefore, were 
excluded. In the final analysis, 10,428 cases were included, or 
40.8% of the total number of SCLC cases diagnosed between 
1992 and 2001. Patients were followed-up until date of death, 
date of censoring, or December 2004.
Staging
SCLC has traditionally been classified as either limited 
stage or extensive stage.8 Limited-stage disease is confined to 
the ipsilateral hemithorax and can be encompassed in a tolera-
ble radiation field. Extensive-stage disease extends beyond the 
ipsilateral hemithorax and may include metastases. The SEER 
database classifies cancers as localized, regional, distant, or 
unstaged. Localized and regional-stage disease is similar to 
limited stage, and distant stage corresponds to extensive stage.
Identification of Treatments
In this study, treatment was defined as surgery and/or 
radiation within the first course of treatment and chemother-
apy within the first 6 months after a diagnosis of SCLC. Six 
months was chosen because chemotherapy is usually admin-
istered over a period of 3 to 5 months and begins a short time 
after diagnosis. Therapeutic and prophylactic cranial irradia-
tion were not assessed because of a lack of data indicating 
which patients had brain metastases. Information on whether 
radiation is given for curative intent or for palliation is not 
available in the SEER-Medicare database. Chemotherapy data 
were divided into four categories: no chemotherapy; etopo-
side with carboplatin or cisplatin with or without other agents 
(EP); CAV; and other combinations. The last two groups did 
not include cisplatin or etoposide.
Comorbidity Data
For outpatient and physician billing claims files, comor-
bidities appearing in at least 2 different months in the 12 
months before diagnosis were included.12 To make the crite-
ria for inclusion of comorbidities more stringent, comorbidi-
ties had to appear in both the outpatient and physician billing 
claims files to be included. All inpatient comorbidities in the 
12 months before the diagnosis of SCLC were included. A 
rule-out algorithm was used to exclude comorbidity codes 
accompanying billing codes for procedures, laboratory tests, 
radiologic tests, or durable medical equipment because they 
may not have been entered by physicians and may not reflect 
true diagnoses.14,15
Using the Deyo adaptation, ICD Ninth Revision, 
Clinical Modification codes were converted into comorbid-
ity variables.16 A comorbidity score was calculated for each 
patient using Cox proportional hazards regression model-
ing with noncancer mortality as the outcome.17 Weighting of 
comorbidities was accomplished by taking the hazard ratio 
(HR) for each comorbidity and rounding to the nearest integer. 
The comorbidity score was calculated by adding the comorbid 
conditions multiplied by their respective weights.15
Statistical Analysis
SCLC cases diagnosed between January 1992 and 
December 2001 were extracted from SEER-Medicare using 
Statistical Analysis Software (SAS) version 9.1 (SAS Institute, 
Cary, NC). Selected files in SEER-Medicare were converted 
from SAS into Stata version 8.2 (StataCorp, College Station, 
TX) using Stat/Transfer version 9. All analyses were con-
ducted in Stata 8.2.
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Patients were stratified according to sex, age at diagnosis, 
race and ethnicity, stage, comorbidities, treatment with surgery, 
radiation, or chemotherapy, and specific chemotherapy catego-
ries. The probability of receiving chemotherapy was analyzed 
according to demographic variables, stage, and treatment. The 
Pearson χ2 test was used for comparisons of proportions.
Logistic regression was used to analyze factors asso-
ciated with the administration of chemotherapy. Univariate 
analyses were performed to determine which confounders 
were statistically significant. Clinically or statistically signifi-
cant variables were added to the model in a stepwise fashion. 
Covariates included in the model were sex, age, race, stage, 
treatment, comorbidity score, SEER registry, and median 
income by census tract.
Overall survival was the primary endpoint of the study 
and was calculated from date of diagnosis to date of death 
or last known date that the patient remained alive. Patients 
who were not deceased were censored at the date they were 
last known to be alive based on the date of their most recent 
contact.
Median survival was calculated for the entire cohort 
while stratifying on sex, age, race, stage, and treatment. 
Kaplan–Meier survival curves were generated to demonstrate 
differences in survival. Evaluating the effects of covariates 
on survival was performed using Cox proportional hazards 
regression modeling. Variables that were significant in the uni-
variate analysis or of clinical significance were included in the 
model. Covariates included were sex, age, race, stage, treat-
ment, comorbidity score, SEER registry, and income. Patients 
were followed for a minimum of 1 month and a maximum 
of 156 months. Two-year survival was examined according to 
year of diagnosis.
Because this is an observational study rather than an 
RCT, a propensity score was used to approximate a random-
ized trial using observational data. Propensity scores attempt 
to equalize confounding factors when evaluating a particular 
outcome. Patients are matched or stratified according to their 
likelihood of receiving chemotherapy.18,19 In this study, logis-
tic regression was used to generate a propensity score for each 
patient, which is the probability of receiving chemotherapy 
based on the following eight variables: sex, age, race, stage, 
treatment with surgery or radiation, comorbidity score, and 
geographic area. The propensity score was divided into 20 
quantiles, from the lowest to the highest, to minimize con-
founding. Median survival for patients receiving or not receiv-
ing each treatment was assessed for each propensity score 
quantile. The median survivals were then averaged, and the 
differences between patients receiving and not receiving che-
motherapy were examined.
Quantile regression was used to predict median survival 
based on sex, age, stage, treatment, comorbidity score, and 
college education. The model provided the survival benefit in 
months for surgery, radiation, and chemotherapy.
RESULTS
Patient Characteristics and Treatment
The total number of patients who fulfilled the eligibil-
ity criteria was 10,428 (Table 1). There were slightly more 
men (5337, 51.2%) than women (5091, 48.8%) with SCLC. 
Median age for both men and women was 73 years. The aver-
age follow-up time for the 10,428 patients in this study was 11 
months, and the total number of person-years was 9592 years. 
At the time of this study, 97.8% of the patients had died. Of 
the patients in this study, 25.3% had at least one comorbidity; 
and the comorbidity score ranged from 0 to 21 points (mean, 
0.53 points). Women had a higher comorbidity score than men 
(p=0.002).
Among all patients in the study, 3.4% received surgery, 
39.1% were treated with radiation, and 67.1% received che-
motherapy. Treatments were divided into nine categories. The 
three most common treatment categories were chemotherapy 
alone (33.3%), radiation and chemotherapy (29.0%), and no 
treatment (21.8%). These data do not distinguish between 
chemotherapy and radiation administered sequentially versus 
concurrently. Most chemotherapy regimens included etoposide 
with cisplatin or carboplatin (etoposide platinum [EP] regimen; 
41.6%). The CAV regimen was given less frequently (1.9%).
Univariate Analysis of Chemotherapy
Statistically significant differences in receipt of che-
motherapy were seen when patients were stratified by age, 
race, stage, radiation, comorbidities, and geographic area 
(Table 2). In this univariate analysis, patients aged 85 years 
and older were less than half as likely to receive chemother-
apy as patients aged 65 to 69 years (34.7% versus 76.1%; 
p<0.001). Blacks were 9% less likely to receive chemotherapy 
than white non-Hispanics (58.9% versus 67.8%; p<0.001). 
Extensive-stage patients received chemotherapy less often 
than limited-stage patients (63.2% versus 72.8%; p<0.001). 
Although there was a difference in the probability of receiving 
chemotherapy for patients who received radiation versus those 
who did not receive radiation (76.9 versus 60.5%; p<0.001), 
there was no difference between patients who were and were 
not treated with surgery. Significant differences in receipt of 
chemotherapy were seen by SEER registry with patients in 
Seattle, Iowa, and rural Georgia being more likely to receive 
chemotherapy than patients in San Francisco.
Multivariate Analysis of Chemotherapy
A multivariate logistic regression model was used to 
control for confounding variables in the evaluation of which 
patients received chemotherapy for SCLC (Table 2). Older 
patients were significantly less likely than younger patients to 
receive chemotherapy (odds ratio [OR] 0.17, 95% confidence 
interval [CI] 0.14–0.21). Black patients were also less likely 
to receive chemotherapy (OR 0.67; 95% CI 0.56–0.81), as 
were patients with extensive-disease (OR 0.61; 95% CI 0.55–
0.67). Patients with a higher comorbidity score had a lower 
odds of receiving chemotherapy. There were no differences 
between men and women and between patients receiving and 
not receiving surgery in the likelihood of receiving chemo-
therapy. Radiation was positively associated with receipt of 
chemotherapy (OR 1.88; 95% CI 1.71–2.06). Patients in the 
highest quartile of median household income had a greater 
odds of receiving chemotherapy than patients in the lowest 
quartile (OR 1.24; 95% CI 1.07–1.43). An interaction term 
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between age and stage and an interaction term between race 
and site were not significant.
Referral Patterns
Overall, 83.4% of patients were referred to a hema-
tologist/oncologist. Among those referred, 80.4% received 
chemotherapy. Older patients, extensive-stage patients, and 
unstaged patients were less likely to be referred to a hema-
tologist/oncologist and less likely to receive chemotherapy if 
they were seen.
Survival in Univariate Analysis
To examine survival, unadjusted Kaplan–Meier sur-
vival curves were generated, stratifying for various covariates 
TABLE 1.  Characteristics and Treatment of Patients with Small-Cell Lung Cancer
Variable
All Patients
N (%)
Ages 65 to  
74 Years
Ages 75 Years 
and Older p-value
Total patients 10,428 6243 4185
Median age in years (range) 73 (65–97)
Men 5337 (51.2%) 3204 (51.3%) 2133 (51.0%) 0.72
Women 5091 (48.8%) 3039 (48.7%) 2052 (49.0%)
Race
  White non-Hispanic 9067 (87.0%) 5383 (86.3%) 3684 (88.0%)  0.004
  White Hispanic  304 (2.9%) 188 (3.0%) 116 (2.8%)
  Black  698 (6.7%) 463 (7.4%) 235 (5.6%)
  Asian  321 (3.1%) 182 (2.9%) 139 (3.3%)
  Native American  33 (0.3%) 22 (0.4%) 11 (0.3%)
SEER stage
  Limited  4241 (40.7%) 2498 (40.0%) 1743 (41.7%)  <0.001
  Extensive 5500 (52.7%) 3371 (54.0%) 2129 (50.9%)
  Unstaged  687 (6.6%) 374 (6.0%) 313 (7.5%)
Comorbidity score
  0 7790 (74.7%) 4762 (76.3%) 3028 (72.4%) <0.001
  1 1203 (11.5%) 713 (11.4%) 490 (11.7%)
  2  659 (6.3%) 361 (5.8%) 298 (7.1%)
  3  381 (3.7%) 197 (3.2%) 184 (4.4%)
  ≥ 4  395 (3.8%) 210 (3.4%) 185 (4.4%)
Treatment
  Any surgery  351 (3.4%) 235 (3.8%) 116 (2.8%) 0.02
  Any radiation 4077 (39.1%) 2739 (43.9%) 1338 (32.0%) <0.001
  Any chemotherapy 6994 (67.1%) 4613 (73.9%) 2381 (56.9%) <0.001
Treatment
  No treatment 2275 (21.8%) 1023 (16.4%) 1252 (29.9%) <0.001
  Surgery only  83 (0.8%) 44 (0.7%) 39 (0.9%) 0.2
  Radiation only  907 (8.7%) 483 (7.7%) 424 (10.1%) <0.001
  Chemotherapy only 3475 (33.3%) 2106 (33.7%) 1369 (32.7%) 0.3
  Surgery and radiation  29 (0.3%) 15 (0.2%) 14 (0.3%) 0.4
  Surgery and chemotherapy  136 (1.3%) 97 (1.6%) 39 (0.9%) 0.006
  Radiation and chemotherapy  3021 (29.0%) 2153 (34.5%) 868 (20.7%) <0.001
  Surgery, radiation, and chemotherapy  90 (0.9%) 69 (1.1%) 21 (0.5%) 0.001
  Unknown if surgery or radiation  412 (4.0%) 253 (4.1%) 159 (4.0%) 0.5
Type of chemotherapya
  No chemotherapy 3434 (32.9%) 1630 (26.1%) 1804 (43.1%) <0.001
  Etoposide with carboplatin or cisplatin (with or without 
other agents)
4337 (41.6%) 2898 (46.4%) 1439 (34.4%) <0.001
  Cyclophosphamide, doxorubicin, and vincristine (with 
other agents)
 202 (1.9%) 134 (2.2%) 68 (1.6%) 0.06
  Other combinations 2455 (23.5%) 1581 (25.3%) 874 (20.9%) <0.001
a These are chemotherapeutic agents given at any time in the first 6 months after a diagnosis of small-cell lung cancer.
SEER, Surveillance, Epidemiology, and End Results.
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TABLE 2.  Univariate Analysis and Logistic Regression Model of Factors Associated with Receiving Chemotherapy for Small-Cell 
Lung Cancer
Factor
Percentage who Received Chemotherapy, 
Univariate Analysis
Odds Ratio, Logistic 
Regression
95% Confidence  
Interval p
Men 67.0 Reference
Women 67.1 0.97 0.89–1.06 0.52
Age group, yr
  65–69 76.1 Reference
  70–74 71.9 0.80 0.71–0.90 <0.001
  75–79 63.7 0.57 0.50–0.64 <0.001
  80–84 50.9 0.33 0.28–0.38 <0.001
  ≥85 34.7 0.17 0.14–0.21 <0.001
Race
  White non-Hispanic 67.8 Reference
  White Hispanic 65.8 1.01 0.78–1.31 0.95
  Black 58.9 0.67 0.56–0.81 <0.001
  Asian 64.8 1.21 0.90–1.63 0.20
  Native American 75.8 1.45 0.64–3.29 0.37
  Unknown 60.0 0.37 0.06–2.45 0.30
SEER stage
  Limited 72.8 Reference
  Extensive 63.2 0.61 0.55–0.67 <0.001
  Unstaged 62.3 0.68 0.49–0.81 <0.001
Lung cancer surgery 66.7 0.81 0.64–1.03 0.08
Radiation 76.9 1.88 1.71–2.06 <0.001
Comorbidity score
  0 69.1 Reference
  1 66.2 0.92 0.81–1.06 0.25
  2 61.5 0.77 0.65–0.91 0.003
  3 53.0 0.56 0.45–0.70 <0.001
  ≥ 4 53.7 0.57 0.46–0.70 <0.001
SEER registry
  San Francisco 59.0 Reference
  Connecticut 67.3 1.44 1.15–1.79 0.001
  Detroit 66.3 1.44 1.17–1.78 0.001
  Hawaii 59.9 1.01 0.69–1.48 0.97
  Iowa 70.7 1.89 1.50–2.37 <0.001
  New Mexico 63.6 1.19 0.89–1.60 0.23
  Seattle 71.9 1.87 1.48–2.37 <0.001
  Utah 62.2 1.23 0.86–1.77 0.26
  Atlanta 67.7 1.54 1.18–2.00 0.001
  San Jose 69.2 1.57 1.16–2.13 0.004
  Los Angeles 65.4 1.39 1.11–1.74 0.005
  Rural Georgia 71.4 2.02 1.01–4.02 0.05
  Greater California 66.5 1.59 1.21–2.08 0.001
  Kentucky 67.1 1.44 1.06–1.95 0.02
  Louisiana 67.7 1.60 1.12–2.27 0.01
  New Jersey 66.2 1.57 1.19–2.08 0.001
Median income by census tract in 1990
  First quartile, < $25,802 65.3 Reference
  Second quartile, $25,803–$33,881 67.0 1.03 0.91–1.17 0.65
  Third quartile, $33,882–$43,291 67.6 1.14 0.99–1.31 0.06
  Fourth quartile, ≥ $43,292 68.8 1.24 1.07–1.43 0.003
SEER, Surveillance, Epidemiology, and End Results.
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(Figure 1). The unadjusted median survival was 7 months 
for all patients, 7 months for men, and 8 months for women. 
Median survival decreased with increasing age. For example, 
patients who were 65–69 years had a median survival of 9 
months compared with a median survival of 3 months for 
patients aged 85 years or more. Median survival for whites, 
blacks, and Native Americans was 7 months; whereas survival 
for Asians was 8 months. Median survival for limited-stage 
disease was 10 months compared with 5 months for exten-
sive-stage disease. In the unadjusted analysis, patients who 
received chemotherapy and radiation had a longer median 
survival (11 months) than patients who received chemother-
apy alone (9 months) or radiation alone (3 months). Treatment 
with EP was associated with a longer median survival (11 
months) than treatment with other combinations (8 months) 
or no chemotherapy (2 months).
Survival in Multivariate Analysis
To adjust for confounding in the assessment of survival, 
multivariate Cox proportional hazards regression was used. 
Survival was significantly correlated with sex, age, race, stage, 
treatment, comorbidity score, and SEER registry (Table 3). 
Women had a significantly better survival compared with men 
(HR 0.91; p<0.001). There was a consistent increase in mor-
tality with increasing age with patients aged 85 years or older 
having an HR of 1.30 (p<0.001) compared with patients aged 
65 to 69 years. Black patients had a statistically significant 
decreased risk of dying compared with white non-Hispanic 
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FIGURE 1.  Kaplan–Meier survival curves of overall survival of patients with small-cell lung cancer.
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patients (HR 0.88; p=0.001) when controlling for chemother-
apy. When chemotherapy was removed from the model (data 
not shown), survival in blacks and white non-Hispanics was 
similar (HR for black patients 1.01 [p=0.89]).
Extensive-stage patients had an inferior survival com-
pared with patients with limited disease (HR 1.78; p<0.001). 
Patients who underwent surgical resection had improved sur-
vival (HR 0.50; p<0.001) as did patients who received radia-
tion (HR 0.78; p<0.001). Chemotherapy with EP conferred a 
significantly improved survival compared with no chemother-
apy (HR 0.37; p<0.001). Chemotherapy with CAV was associ-
ated with an HR of 0.47 (p<0.001). The 95% CIs for EP and 
CAV did not overlap, suggesting that EP is a superior regimen. 
When all chemotherapy categories were combined, the HR in 
the multivariate model was 0.40 (p<0.001; data not shown). 
Small differences in survival were seen among various SEER 
regions, but not by income. Not surprisingly, having a higher 
comorbidity score was associated with a higher mortality. 
A sensitivity analysis using less-stringent criteria to assess 
comorbidities (such that comorbid conditions were counted 
if they appeared twice anywhere in the billing records) did 
not significantly change the model (data not shown). Two-year 
survival for SCLC did not improve from 1992 to 2001 and 
ranged from 7.1% to 9.6%.
Propensity Score
To determine the benefit of chemotherapy administra-
tion while controlling for confounding variables, a propensity 
score was used. This was derived from a logistic regression 
model with chemotherapy versus no chemotherapy as the out-
come. The median survival for patients receiving no chemo-
therapy ranged from 2 to 8 months across the 20 quantiles. 
The median survival for patients who did receive chemo-
therapy ranged from 6 to 15 months across 20 quantiles. The 
unweighted averages of the median survivals for patients not 
receiving chemotherapy were compared with the unweighted 
averages of the median survivals for the chemotherapy patients 
(Table 4).
Median survival for patients not receiving chemotherapy 
was 2.6 months compared with 9.5 months for those receiv-
ing chemotherapy. Accordingly, receiving chemotherapy 
TABLE 3.  Multivariate Cox Proportional Hazards Regression 
Model of Patients with Small-Cell Lung Cancer
Factor
Hazard 
Ratio
95% 
Confidence 
Interval p-value
Men Reference
Women 0.91 0.87–0.94 <0.001
Age group, yr
  65–69 Reference
  70–74 1.09 1.04–1.15 0.001
  75–79 1.21 1.14–1.28 <0.001
  80–84 1.23 1.15–1.32 <0.001
  ≥85 1.30 1.17–1.44 <0.001
Race
  White non-Hispanic Reference
  White Hispanic 1.00 0.88–1.12 0.96
  Black 0.88 0.81–0.96 0.003
  Asian 0.99 0.87–1.14 0.93
  Native American 1.03 0.73–1.47 0.85
  Unknown 0.89 0.33–2.37 0.81
SEER stage
  Limited Reference
  Extensive 1.78 1.70–1.85 <0.001
  Unstaged 0.93 0.86–1.02 0.11
Lung cancer surgery 0.50 0.44–0.56 <0.001
Radiation 0.78 0.75–0.81 <0.001
Chemotherapy
  No chemotherapy Reference
  Etoposide with carboplatin or 
  cisplatin (with or without other 
agents)
0.37 0.36–0.39 <0.001
  Cyclophosphamide, doxorubicin, 
 vincristine (with other agents)
0.46 0.40–0.54 <0.001
  Other combinations 0.47 0.44–0.50 <0.001
Comorbidity score
  0 Reference
  1 1.10 1.04–1.17 0.002
  2 1.08 0.99–1.17 0.07
  3 1.24 1.12–1.38 <0.001
  ≥ 4 1.26 1.14–1.40 <0.001
SEER registry
  San Francisco Reference
  Connecticut 1.04 0.94–1.15 0.47
  Detroit 1.12 1.01–1.23 0.03
  Hawaii 0.91 0.76–1.09 0.32
  Iowa 1.02 0.92–1.14 0.67
  New Mexico 1.02 0.89–1.17 0.76
  Seattle 1.03 0.93–1.15 0.54
  Utah 1.28 1.08–1.51 0.005
  Atlanta 1.05 0.93–1.18 0.47
  San Jose 1.02 0.89–1.18 0.74
  Los Angeles 1.12 1.01–1.24 0.04
  Rural Georgia 1.11 0.82–1.50 0.51
  Greater California 1.09 0.95–1.23 0.21
TABLE 3.  (Continued)
Factor
Hazard 
Ratio
95% 
Confidence 
Interval p-value
  Kentucky 1.17 1.02–1.34 0.03
  Louisiana 1.35 1.15–1.59 <0.001
  New Jersey 1.09 0.95–1.23 0.21
Median Income by Census Tract  
 in 1990
  First quartile, < $25,802 Reference
  Second quartile, $25,803-$33,881 1.02 0.97–1.08 0.44
  Third quartile, $33,882-$43,291 0.99 0.93–1.05 0.74
  Fourth quartile, ≥ $43,292 1.04 0.97–1.11 0.25
SEER, Surveillance, Epidemiology, and End Results.
(Continued)
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improved median survival by an average of 6.9 months after 
controlling for known confounders. For men, the benefit of 
chemotherapy was 6.3 months, whereas for women, it was 8.1 
months. Chemotherapy conferred a benefit in survival for all 
age groups, races, and stages, with an improvement in median 
survival ranging from 5.5 to 8.1 months. Even patients aged 
85 and older derived a similar benefit from chemotherapy 
compared with patients 65 to 69 years old.
Quantile Regression
Multivariate quantile regression was used to develop a 
model for the prediction of median survival in elderly patients 
with SCLC (Table 5). Factors associated with an improved 
median survival included being female (+0.37 months; 95% 
CI, +0.26 to +0.49), receiving treatment of any kind, and liv-
ing in an area where a relatively high proportion of people 
have a college degree. Undergoing surgery conferred a sur-
vival benefit of 5.40 months (95% CI; +5.07 to +5.72), radia-
tion 1.47 months (95% CI; +1.30 to +1.64), and chemotherapy 
6.45 months (95% CI; +6.32 to +6.58).
Variables associated with a worse survival included hav-
ing extensive-stage disease (−2.65 months, 95% CI, −2.80 to 
−2.50) and a higher comorbidity score. Unlike the results of 
our Cox regression model, in the quantile regression model, 
race was not significantly associated with survival and was 
dropped from the model. Separate quantile regression mod-
els for men and women showed that chemotherapy improved 
survival by 6 months for men and 7.5 months for women, con-
firming the results of our propensity score analysis. When an 
interaction term for sex and chemotherapy was added to the 
quantile regression model, it was significant (p<0.001), indi-
cating an enhanced benefit of chemotherapy for women com-
pared with men (data not shown).
This quantile regression model can be used to estimate 
survival after diagnosis. For example, a 65-year-old man with 
extensive-stage SCLC has a comorbidity score of 0 and receives 
chemotherapy alone. His predicted survival according to this 
model is 8.2 months. Usage of the propensity score and quantile 
regression techniques yielded similar results with chemother-
apy benefiting men and women and all ages, races, and stages.
DISCUSSION
This retrospective cohort study was designed to examine 
factors associated with chemotherapy administration among 
elderly patients with SCLC in the community and to quantify 
the survival benefit. To our knowledge, this is the largest pub-
lished study of SCLC. Among 10,428 patients aged 65 years 
and older who were diagnosed with SCLC between 1992 and 
2001 in this study, 67.1% received chemotherapy, most of 
whom (41.6%) received EP.
Receipt of chemotherapy was inversely correlated with 
age; patients in the oldest age group were less than half as 
TABLE 5.  Quantile Regression of Median Survival in Months 
for Small-Cell Lung Cancer
Variable
Median  
Survival  
in Months
95% 
Confidence 
Interval p
Constant +4.44 +3.67 to +5.22 <0.001
Men Reference
Women +0.37 +0.26 to +0.49 <0.001
Age group, yr
  65–69 Reference
  70–74 −0.53 −0.70 to −0.37 <0.001
  75–79 −0.73 −0.95 to −0.52 <0.001
  80–84 −0.76 −1.07 to −0.46 <0.001
  ≥85 −1.40 −1.85 to −0.94 <0.001
SEER stage
  Limited Reference
  Extensive −2.65 −2.80 to −2.50 <0.001
  Unstaged +0.37 +0.11 to +0.63 0.005
Surgery +5.40 +5.07 to +5.72 <0.001
Radiation +1.47 +1.30 to +1.64 <0.001
Chemotherapy +6.45 +6.32 to +6.58 <0.001
Comorbidity Score
  0 Reference
  1 −0.17 −0.36 to +0.01 0.07
  2 −0.35 −0.60 to −0.11 0.005
  3 −0.84 −1.16 to −0.51 <0.001
  ≥4 −0.88 −1.21 to -0.55 <0.001
College education* +0.29 +0.13 to +0.45 <0.001
Propensity score −0.14 −1.10 to +0.82 0.78
At least 29% of people with a college degree by census tract.
SEER, Surveillance, Epidemiology, and End Results.
TABLE 4.  Differences in Median Survival in Months for 
Patients Receiving Chemotherapy Versus No Chemotherapy 
Using Propensity Scores
No  
Chemotherapy Chemotherapy
Difference in 
Survival
All patients 2.6 9.5 6.9
  Men 2.8 9.1 6.3
  Women 2.4 10.5 8.1
Age group, yr
  65–69 2.8 9.9 7.1
  70–74 2.6 9.9 7.3
  75–79 3.0 9.4 6.4
  80–84 4.8 10.3 5.5
  ≥85 2.9 9.3 6.4
Race
  White non-
Hispanic
2.5 9.5 7.0
  White Hispanic 3.5 9.0 5.5
  Black 3.8 10.1 6.2
  Asian 4.1 9.7 5.6
SEER stage
  Limited 3.9 10.7 6.9
  Extensive 3.2 10.4 7.2
  Unstaged 6.2 12 5.8
SEER, Surveillance, Epidemiology, and End Results.
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likely to receive chemotherapy as patients in the youngest age 
group. Earle et al.20 demonstrated that with each incremental 
decade of life, the OR for receiving chemotherapy for meta-
static NSCLC was 0.46 (95% CI 0.41–0.51). Black patients 
in this study were less likely to be treated with chemotherapy 
compared with non-Hispanic whites in the univariate analysis 
and the multivariate analysis. A racial difference in chemo-
therapy was also seen in the study by Earle et al., where the 
OR for receiving chemotherapy was 0.70 (95% CI 0.55–0.88) 
for black patients with NSCLC compared with non-Hispanic 
white patients. In our study, black patients were less likely 
to be referred to a hematologist/oncologist, but were equally 
likely to receive chemotherapy if referred.
A higher comorbidity score was associated with a 
decreased likelihood of receiving chemotherapy. A higher 
comorbidity score may indicate worse performance status; 
however, information about performance status was not avail-
able. Even income was positively correlated with chemother-
apy administration, despite all patients in this study having the 
same insurance. Note, however, that the income provided is the 
average for each census area and not for individual patients.
As illustrated in the multivariate Cox regression model, 
chemotherapy had a significant impact on survival, with HRs 
of 0.37 to 0.47. Chemotherapy with EP offered the most dra-
matic risk reduction (HR 0.37). The CAV regimen and other 
combinations were associated with HRs of 0.46 to 0.47. These 
HRs were far superior to HRs reported for metastatic NSCLC 
patients who receive chemotherapy (0.78–0.85).21 This reflects 
the high responsiveness that SCLC has to chemotherapy. 
Nonetheless, the vast majority of patients relapse, as reflected 
by the poor median survival in this cohort.
In our multivariate survival model, women had better 
survival than men after controlling for other factors. This 
trend has also been seen in NSCLCs with HRs ranging from 
0.78 to 0.91 in one study and in lung cancer with all histolo-
gies in another SEER study (relative 5-year survival 17.3% 
for women versus 13.8% for men).22,23 Improved survival 
for women may reflect genetic and hormonal differences in 
women.24
The unadjusted median survival for patients in this study 
was only 7 months compared with 17 months for limited-stage 
patients and 8.9 months for extensive-stage patients in the 
control arms of RCTs.6,7 Inferior survival in our study likely 
reflects older age and greater comorbidities of this cohort 
compared with those of patients included in RCTs.
Many RCTs in SCLC compare different chemotherapy 
regimens, rather than comparing chemotherapy with BSC. 
The first data supporting a role for chemotherapy in SCLC 
was based upon a 1969 report of an RCT conducted by the 
Veterans Administration Lung Cancer Study Group.25 Among 
those receiving cyclophosphamide, median survival was more 
than 4 months compared with less than 2 months among 
placebo-treated patients (p=0.0005). A systematic review of 
RCTs comparing chemotherapy with BSC in extensive SCLC 
concluded that chemotherapy conferred a survival advantage 
of 2.6 months.26 Despite limited data from randomized trials 
that chemotherapy is superior to BSC in SCLC, combination 
chemotherapy has been recognized as having a pivotal role in 
SCLC management since the early 1970s.6,7
In this study, chemotherapy was demonstrated to improve 
survival for all age groups, races, and stages. Women derived 
a greater survival benefit from chemotherapy than males. 
Although older patients, black patients, and patients with exten-
sive-stage disease were less likely to be treated with chemother-
apy, they all derived a significant benefit from the administration 
of chemotherapy. Improvement in survival associated with che-
motherapy was 6.9 months using the propensity score analysis 
and 6.5 months using quantile regression. Quantile regression 
can be used to predict prognosis for elderly patients with SCLC. 
This model has been shown to have internal validity but has not 
been tested using an independent data source.
The main limitation of this study is that it is an obser-
vational rather than a randomized trial. Despite the use of rig-
orous statistical methods to control for confounders, residual 
confounding may still remain. Other limitations include the 
lack of information about smoking and brain metastases, 
which precluded an analysis of prophylactic cranial irradia-
tion. The results of this study are generalizable for patients 
aged 65 years and older with SCLC because the data are taken 
from geographical areas representing 26% of the U.S. popula-
tion and because Medicare captures 97% of elderly patients.
In conclusion, our study demonstrates that treatment 
with chemotherapy is associated with a statistically significant 
greater than 6-month improvement in median survival among 
elderly patients with SCLC. One third of elderly patients with 
SCLC never receive chemotherapy, and one sixth are never 
referred to a medical oncologist, suggesting that chemother-
apy is underused. This large retrospective cohort study is the 
first study to quantify the survival benefit of chemotherapy 
for SCLC in the community. Despite methodological limita-
tions, our study provides strong evidence that chemotherapy 
improves survival in elderly patients with SCLC.
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